Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;30(33):2619-2630.
doi: 10.2174/0113816128317605240628063731.

Nanotechnological Advances in the Diagnosis of Gynecological Cancers and Nanotheranostics

Affiliations
Review

Nanotechnological Advances in the Diagnosis of Gynecological Cancers and Nanotheranostics

Vahideh Keyvani et al. Curr Pharm Des. 2024.

Abstract

Gynecological cancers are one of the main causes of female mortality worldwide. Despite the various strategies to reduce mortality and improve quality of life, there are still many deficiencies in the diagnosis and treatment of gynecological cancers. One of the important steps to ensure optimal cancer treatment is the early detection of cancer cells and the use of drugs to reduce toxicity. Due to the increase in systemic toxicity and resistance to traditional and conventional diagnostic methods, new strategies, including nanotechnology, are being used to improve diagnosis and reduce the severity of the disease. Nanoparticles (NPs) provide exciting opportunities to improve Gynecological Cancers (GCs) diagnosis, particularly in the initial stages. In biomedical investigations and clinical settings, NPs can be used to increase the sensitivity and specificity of recognition and/or imaging of GCs with the help of their molecular and cellular processes. To design more efficient diagnostic NPs for gynecological cancer cells or tissues, determining the specific biomarkers is of great importance. NP-based imaging agents are another solution to trace cancer cells. This review highlights the potential of some NP-based diagnostic techniques in GC detection, which could be translated to clinical settings to improve patient care.

Keywords: NP-based diagnostics; cancer cells.; cervical cancer; gynecological cancer diagnosis; nanotechnological platforms; ovarian cancer.

PubMed Disclaimer

References

    1. Ferlay J.; Soerjomataram I.; Dikshit R.; Eser S.; Mathers C.; Rebelo M.; Parkin D.M.; Forman D.; Bray F.; Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015,136(5),E359-E386 - DOI - PubMed
    1. Mandilaras V.; Karakasis K.; Clarke B.; Oza A.; Lheureux S.; Rare tumors in gynaecological cancers and the lack of therapeutic options and clinical trials. Expert Opin Orphan Drugs 2017,5(1),71-83 - DOI
    1. Siegel R.L.; Miller K.D.; Jemal A.; Cancer statistics, 2019. CA Cancer J Clin 2019,69(1),7-34 - DOI - PubMed
    1. Matulonis U.A.; Sood A.K.; Fallowfield L.; Howitt B.E.; Sehouli J.; Karlan B.Y.; Ovarian cancer. Nat Rev Dis Primers 2016,2(1),16061 - DOI - PubMed
    1. Jelovac D.; Armstrong D.K.; Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin 2011,61(3),183-203 - DOI - PubMed

LinkOut - more resources